184 related articles for article (PubMed ID: 33599863)
1. Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq.
Lanceta L; Lypova N; O'Neill C; Li X; Rouchka E; Chesney J; Imbert-Fernandez Y
Breast Cancer Res Treat; 2021 Apr; 186(3):677-686. PubMed ID: 33599863
[TBL] [Abstract][Full Text] [Related]
2. Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer Cells.
Lanceta L; O'Neill C; Lypova N; Li X; Rouchka E; Waigel S; Gomez-Gutierrez JG; Chesney J; Imbert-Fernandez Y
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344635
[TBL] [Abstract][Full Text] [Related]
3. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
Asghar US; Barr AR; Cutts R; Beaney M; Babina I; Sampath D; Giltnane J; Lacap JA; Crocker L; Young A; Pearson A; Herrera-Abreu MT; Bakal C; Turner NC
Clin Cancer Res; 2017 Sep; 23(18):5561-5572. PubMed ID: 28606920
[No Abstract] [Full Text] [Related]
4. Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
Liu CY; Lau KY; Hsu CC; Chen JL; Lee CH; Huang TT; Chen YT; Huang CT; Lin PH; Tseng LM
PLoS One; 2017; 12(12):e0189007. PubMed ID: 29261702
[TBL] [Abstract][Full Text] [Related]
5. Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.
Pandey K; Lee E; Park N; Hur J; Cho YB; Katuwal NB; Kim SK; Lee SA; Kim I; An HJ; Hwang S; Moon YW
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33504001
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
Zhu X; Chen L; Huang B; Li X; Yang L; Hu X; Jiang Y; Shao Z; Wang Z
J Exp Clin Cancer Res; 2021 Apr; 40(1):122. PubMed ID: 33832512
[TBL] [Abstract][Full Text] [Related]
7. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy.
Foidart P; Yip C; Radermacher J; Blacher S; Lienard M; Montero-Ruiz L; Maquoi E; Montaudon E; Château-Joubert S; Collignon J; Coibion M; Jossa V; Marangoni E; Noël A; Sounni NE; Jerusalem G
Clin Cancer Res; 2019 Mar; 25(6):1838-1850. PubMed ID: 30504427
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome Profiling of Cisplatin Resistance in Triple-negative Breast Cancer: New Insight into the Role of PI3k/Akt Pathway.
Memar M; Farazmandfar T; Sabaghian A; Shahbazi M; Golalipour M
Curr Mol Med; 2023; 23(6):559-568. PubMed ID: 35585821
[TBL] [Abstract][Full Text] [Related]
9. Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
Lorito N; Bacci M; Smiriglia A; Mannelli M; Parri M; Comito G; Ippolito L; Giannoni E; Bonechi M; Benelli M; Migliaccio I; Malorni L; Chiarugi P; Morandi A
Cells; 2020 Mar; 9(3):. PubMed ID: 32164162
[TBL] [Abstract][Full Text] [Related]
10. Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway.
Chen L; Yang G; Dong H
Med Sci Monit; 2019 Jan; 25():77-86. PubMed ID: 30605443
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells.
Cretella D; Fumarola C; Bonelli M; Alfieri R; La Monica S; Digiacomo G; Cavazzoni A; Galetti M; Generali D; Petronini PG
Sci Rep; 2019 Sep; 9(1):13014. PubMed ID: 31506466
[TBL] [Abstract][Full Text] [Related]
12. The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.
Cretella D; Ravelli A; Fumarola C; La Monica S; Digiacomo G; Cavazzoni A; Alfieri R; Biondi A; Generali D; Bonelli M; Petronini PG
J Exp Clin Cancer Res; 2018 Mar; 37(1):72. PubMed ID: 29587820
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib.
Yu Y; Liao H; Xie R; Zhang Y; Zheng R; Chen J; Zhang B
Front Oncol; 2020; 10():590813. PubMed ID: 33330073
[TBL] [Abstract][Full Text] [Related]
14. The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D
Vanhevel J; Verlinden L; Loopmans S; Doms S; Janssens I; Bevers S; Stegen S; Wildiers H; Verstuyf A
Front Endocrinol (Lausanne); 2022; 13():886238. PubMed ID: 35784555
[TBL] [Abstract][Full Text] [Related]
15. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
Jansen VM; Bhola NE; Bauer JA; Formisano L; Lee KM; Hutchinson KE; Witkiewicz AK; Moore PD; Estrada MV; Sánchez V; Ericsson PG; Sanders ME; Pohlmann PR; Pishvaian MJ; Riddle DA; Dugger TC; Wei W; Knudsen ES; Arteaga CL
Cancer Res; 2017 May; 77(9):2488-2499. PubMed ID: 28249908
[TBL] [Abstract][Full Text] [Related]
16. Differential Expression and Pathway Analysis in Drug-Resistant Triple-Negative Breast Cancer Cell Lines Using RNASeq Analysis.
Shaheen S; Fawaz F; Shah S; Büsselberg D
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29921827
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing reveals altered gene expression and enriched pathways in triple-negative breast cancer cells treated with oleuropein and oleocanthal.
Karousi P; Kontos CK; Papakotsi P; Kostakis IK; Skaltsounis AL; Scorilas A
Funct Integr Genomics; 2023 Sep; 23(4):299. PubMed ID: 37707691
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
20. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]